November 24, 2016 - By Clifton Ray · 0 Comments
The stock of Alder Biopharmaceuticals Incorporated (NASDAQ:ALDR) registered an increase of 0.09% in short interest. ALDR’s total short interest was 7.87M shares in November as published by FINRA. Its up 0.09% from 7.86 million shares, reported previously. With 573,500 shares average volume, it will take short sellers 14 days to cover their ALDR’s short positions. The short interest to Alder Biopharmaceuticals Incorporated’s float is 22.08%. The stock increased 1.19% or $0.3 on November 23, hitting $25.6. About 827,253 shares traded hands or 13.73% up from the average. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has declined 11.33% since April 22, 2016 and is downtrending. It has underperformed by 16.74% the S&P500.
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $1.23 billion. The Firm discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. It currently has negative earnings. The Firm has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.
Out of 9 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 9 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $72 is the highest target while $40 is the lowest. The $48.29 average target is 88.63% above today’s ($25.6) stock price. Alder Biopharmaceuticals has been the topic of 11 analyst reports since August 6, 2015 according to StockzIntelligence Inc. As per Thursday, April 21, the company rating was reinitiated by Wells Fargo. As per Wednesday, September 9, the company rating was initiated by Jefferies. On Tuesday, September 13 the stock rating was initiated by JP Morgan with “Overweight”. Jefferies maintained Alder Biopharmaceuticals Inc (NASDAQ:ALDR) rating on Wednesday, July 27. Jefferies has “Buy” rating and $62 price target. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, March 29. On Wednesday, April 20 the stock rating was initiated by Brean Capital with “Buy”. The stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has “Overweight” rating given on Monday, October 31 by Piper Jaffray.
Another recent and important Alder Biopharmaceuticals Inc (NASDAQ:ALDR) news was published by Fool.com which published an article titled: “Why Alder Biopharmaceuticals Is Sky-Rocketing Today” on March 28, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray